CA3176265A1 - Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity - Google Patents

Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Info

Publication number
CA3176265A1
CA3176265A1 CA3176265A CA3176265A CA3176265A1 CA 3176265 A1 CA3176265 A1 CA 3176265A1 CA 3176265 A CA3176265 A CA 3176265A CA 3176265 A CA3176265 A CA 3176265A CA 3176265 A1 CA3176265 A1 CA 3176265A1
Authority
CA
Canada
Prior art keywords
mop
mixture
group
disorder
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3176265A
Other languages
English (en)
French (fr)
Inventor
Kai Gerlach
Barbara Bertani
Marco Ferrara
Giacomo FOSSATI
Scott Hobson
Uta Friederike Lessel
Frank Runge
Graeme Semple
Ursula Mueller-Vieira
Julian WIPPICH
Yifeng Xiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Arena Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Arena Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of CA3176265A1 publication Critical patent/CA3176265A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3176265A 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity Pending CA3176265A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
US63/001,640 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (1)

Publication Number Publication Date
CA3176265A1 true CA3176265A1 (en) 2021-10-07

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3176265A Pending CA3176265A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Country Status (20)

Country Link
US (1) US11780827B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126850B1 (cg-RX-API-DMAC7.html)
JP (1) JP7617134B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220161454A (cg-RX-API-DMAC7.html)
CN (1) CN115697997B (cg-RX-API-DMAC7.html)
AR (1) AR121675A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021250303A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176265A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014886A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220554A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000203A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080683A (cg-RX-API-DMAC7.html)
IL (1) IL296823A (cg-RX-API-DMAC7.html)
JO (1) JOP20220235A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022012067A (cg-RX-API-DMAC7.html)
PE (1) PE20221918A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552553A1 (cg-RX-API-DMAC7.html)
TW (1) TW202204343A (cg-RX-API-DMAC7.html)
WO (1) WO2021198149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
WO2023041432A1 (en) 2021-09-14 2023-03-23 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361149A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
EP2518054A1 (en) * 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
AU2021250303A1 (en) 2022-09-22
US11780827B2 (en) 2023-10-10
IL296823A (en) 2022-11-01
JOP20220235A1 (ar) 2022-09-28
MX2022012067A (es) 2022-10-13
DOP2022000203A (es) 2022-11-30
ECSP22080683A (es) 2022-11-30
TW202204343A (zh) 2022-02-01
CO2022014886A2 (es) 2022-10-31
PE20221918A1 (es) 2022-12-29
KR20220161454A (ko) 2022-12-06
JP2023522307A (ja) 2023-05-30
BR112022018996A2 (pt) 2022-11-01
WO2021198149A1 (en) 2021-10-07
CN115697997B (zh) 2024-07-30
EP4126850B1 (en) 2024-04-17
AR121675A1 (es) 2022-06-29
EP4126850A1 (en) 2023-02-08
US20220356172A1 (en) 2022-11-10
CR20220554A (es) 2023-01-09
CN115697997A (zh) 2023-02-03
PH12022552553A1 (en) 2024-01-03
JP7617134B2 (ja) 2025-01-17

Similar Documents

Publication Publication Date Title
JP7846113B2 (ja) 置換ピペリジノ化合物及び関連する治療方法
US11780827B2 (en) Substituted 3-phenoxyazetidin-1-yl-pyrazines
AU2016270677B2 (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
US20230010299A1 (en) Heterocyclic trpml1 agonists
TW201514154A (zh) 適用於治療對多巴胺d3受體調節有反應的病症之醯胺基環烷基化合物
US20080318941A1 (en) 4' substituted compounds having 5-ht6 receptor affinity
CA2632893C (en) (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders
CA3246226A1 (en) C4-substituted tryptamine derivatives and methods of use
KR101567116B1 (ko) Nk1 수용체 길항제로서의 5-[5-[2-(3,5-비스(트리플루오로메틸)페닐)-2-메틸프로파노일메틸아미노]-4-(4-플루오로-2-메틸페닐)]-2-피리디닐-2-알킬-프롤린아미드
EP1891056B1 (en) Novel compounds
EP4402138B1 (en) 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
NO309190B1 (no) Neurobeskyttende kromanforbindelser og farmasöytisk blanding
EP1083178B1 (en) Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof
EP2266976B1 (en) Fused ring thrombin receptor antagonists
CA2927527C (en) Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof as u-opioid receptor antagonist
US9604926B2 (en) Highly selective sigma receptor radioligands
KR20200123416A (ko) 이중 5-ht2a 및 5-ht6 수용체 대항제들로서의 인돌 및 벤즈이미다졸 유도체들
CA3097818A1 (en) 1-imidazothiadiazolo-2h-pyrrol-5-one derivatives
JP2021104931A (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
Bedürftig et al. Synthesis and receptor binding studies of 3-substituted piperazine derivatives
PL245933B1 (pl) (Chinolino lub izochinolino) sulfonamidy amin cyklicznych, kompozycja je zawierająca, sposób ich wytwarzania oraz ich zastosowanie medyczne
US20190062305A1 (en) Pyridyl or pyrazinyl compounds carrying a methyl-bound alpha-amino acid amide group
CN117820202A (zh) 一种胺基甲酸类化合物及其作为Sigma2和5HT2A双靶标抑制剂的用途
US20100190764A1 (en) Novel compounds
US20090099187A1 (en) Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor